TransCon PTH Normalizes Calcium, Reduces Need for Added Therapies

TransCon PTH Normalizes Calcium, Reduces Need for Added Therapies

312600

TransCon PTH Normalizes Calcium, Reduces Need for Added Therapies

TransCon PTH normalized calcium levels in the blood and urine of adults with hypoparathyroidism and eliminated the need for vitamin D supplements and high doses of calcium, according to more than 1.5 years of trial data. This data — 84 weeks’ worth in all — came from the global PaTH Forward Phase 2 trial, which involved 59 hypoparathyroidism patients, and its open-label extension. “We believe that these data, combined with nearly all patients continuing in…

You must be logged in to read/download the full post.